Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Opioid Stories

2014-01-04 23:24:08

Aid in Recovery released a statement today commenting on a recent study into the effectiveness of Naltrexone in treating addiction to opioids. Aid in Recovery has said that it will stay abreast of all clinical research regarding this drug, in order to better serve their patients. West Palm Beach, Florida (PRWEB) January 03, 2014 Aid in Recovery released a statement today commenting on recent research into the effectiveness of the drug Nalltrexone in the treatment of opiod addiction. The...

2013-12-16 08:26:22

LEXINGTON, MA, December 16, 2013 /PRNewswire/ -- Patent Provides Composition of Matter Protection for a Series of Highly Selective Delta Opioid Receptor Agonists Biousian Biosystems Inc, (BBI) a biotechnology company that designs and develops drugs with unique selectivity and potency for GPCR targets, today announced that the U.S. Patent and Trademark Office has issued a patent to BBI (U.S. Patent 8,575,309). The patent describes a series of highly selective and potent...

2013-12-13 08:24:43

- 30 mcg sufentanil NanoTab treatment group experienced rapid onset of action with statistically significant pain relief and reduced pain intensity at 30 minutes - REDWOOD CITY, Calif., Dec. 13, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today presented additional detail from the Phase 2 dose-finding study...

2013-12-04 16:25:35

NORTH LIBERTY, Iowa, Dec. 4, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Oppenheimer 24(th) Annual Healthcare Conference being held in New York City December 10-11, 2013. Among the topics to be discussed, Dr. Mickle will provide an overview of KP201, the company's lead clinical candidate...

2013-12-03 16:25:16

LONDON, Dec. 3, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, has announced that the initial findings of its clinical trial with the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health, supports Lightlake's intranasal delivery of naloxone as a promising innovative treatment for opioid overdose....

Oxycodone, Hydrocodone Drugs Of Choice For Opioid Abusers
2013-12-03 07:37:18

April Flowers for redOrbit.com - Your Universe Online In the past 15 years, prescription opioid abuse has reached epidemic levels. Researchers investigating why abusers favor one prescription medication over another have discovered that oxycodone and hydrocodone are the drugs of choice for 75 percent of opioid-dependent people. Oxycodone is the most popular drug over all, according to a study published in the journal PAIN, because of the high quality of the high for those who were after...

2013-11-29 13:15:30

A ground-breaking international collaborative survey, published today in Annals of Oncology, shows that more than half of the world's population live in countries where regulations that aim to stem drug misuse leave cancer patients without access to opioid medicines for managing cancer pain. The results from the Global Opioid Policy Initiative (GOPI) project show that more than 4 billion people live in countries where regulations leave cancer patients suffering excruciating pain....

2013-11-26 08:27:16

STAMFORD, Conn., Nov. 26, 2013 /PRNewswire/ -- Purdue Pharma L.P. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for Targiniq(TM) ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain. "This milestone brings us closer to offering an important treatment option for the management of chronic pain," said Gary L. Stiles, MD, Purdue Pharma's Senior Vice President of...

2013-11-20 23:22:52

Modern Medical, a Healthcare Solutions company, today announced outcomes for its Opioid Defense Manager™ (ODM) program. Launched in November 2012, ODM is Modern Medical’s managed care program to stop the rising opioid abuse in the workers’ compensation industry by reducing inappropriate drug use and still maintaining the necessary balance to provide pain relief for the claimant. Columbus, OH (PRWEB) November 20, 2013 Modern Medical, a Healthcare Solutions company, today announced...

2013-11-19 08:27:33

SAN FRANCISCO, Nov. 19, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, the most common side effect( )caused by chronic...